https://www.live-feeds.com/feed/cholesterol-drug-setback-casts-doubt-over-multibillion-dollar-raceContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/cholesterol-drug-setback-casts-doubt-over-multibillion-dollar-racehttps://www.live-feeds.com/feed/cholesterol-drug-setback-casts-doubt-over-multibillion-dollar-race#u62456Wed, 09 Sep 2026 07:11:01 +0000Novartis faces a major setback after its experimental cardiovascular drug failed a crucial phase 3 test. The failed treatment served as the centerpiece of a 12 billion dollar buyout. This development shocked cardiologists and cast doubt over a multibillion-dollar race in the pharmaceutical sector. The negative trial results also dragged down the Dow as markets reacted to the Swiss company's bad news.Why it mattersExperimental cardiovascular and cholesterol treatments attract massive financial investments across the pharmaceutical industry. Major company acquisitions hinge on the clinical